Allogene Therapeutics (ALLO) Net Margin (2021 - 2026)

Allogene Therapeutics has reported Net Margin for 4 years, with the latest figure at 353104.55% in Q1 2024.

• Quarterly Net Margin fell 1966121.0% year-over-year to 353104.55% in Q1 2024, while the trailing twelve-month figure through Dec 2024 was 1844954.55% (down 144767665.0% YoY) and the FY2024 annual result came in at 1170863.64%, down 82637416.0% from the prior year.
• Net Margin slipped to 353104.55% in Q1 2024 per ALLO's latest filing, from 346876.19% in the prior quarter.
• Over five years, Net Margin peaked at 4.05% in Q4 2021 and troughed at 833066.67% in Q3 2022.
• A 4-year average of 324906.08% and a median of 333947.73% in 2021 frame the typical range for Net Margin.
• The sharpest annual moves came in 2022 and 2023: Net Margin plunged 50573401 bps in 2022, then surged 41701212 bps in 2023.
• Over 4 years, Net Margin stood at 4.05% in 2021, then plunged by 9541221 bps to 386684.62% in 2022, then grew by 10 bps to 346876.19% in 2023, then slipped by 2 bps to 353104.55% in 2024.
• According to Business Quant data, Net Margin over the past three periods registered 353104.55%, 346876.19%, and 416054.55% for Q1 2024, Q4 2023, and Q3 2023 respectively.